

Good afternoon,

I am writing in regard to a concern my colleagues and I have with the Iowa Medicaid preferred drug list items for granulocyte colony-stimulating factors (G-CSF). Our pediatric patients undergoing chemotherapy treatment routinely need GCSF support as part of their treatment protocols. Recently the Medicaid PDL preferred product was switched to the biosimilar product tbo-filgrastim (Granix). I am inquiring as to how we can bring this to the table for discussion, as filgrastim-sndz (Zarxio) and Neupogen would be preferred in our patient population due to the pediatric data supporting their use, as well as the availability of a vial for the Neupogen product for partial doses (as the other products are prefilled syringes). We are having problems getting Zarxio and Neupogen approved through Amerigroup MCO and it is causing delays in pediatric patients getting appropriate treatment. I appreciate any guidance you can provide on how we can address this concern.

Thank you,